![]() |
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
Sponsors and Collaborators: |
Weill Medical College of Cornell University Forest Laboratories |
---|---|
Information provided by: | Weill Medical College of Cornell University |
ClinicalTrials.gov Identifier: | NCT00754936 |
The purpose of this study is to examine the relationship between brain electrical activity in elderly depressed patients and response to antidepressant medication treatment. Elderly patients with depression will be treated for 12 weeks with an antidepressant medication commonly used in clinical practice called escitalopram (Lexapro). Brain electrical activity will be assessed using electrophysiological tests. Researchers are interested in whether the brain electrical activity of elderly people with depression before they start the medication can tell us who amongst them will improve with antidepressant treatment and to what extent. They will also determine whether patients' brain electrical activity during the 12 weeks of medication treatment will change in any way and whether this change will be linked with a change in the severity of their depression. Researchers hope that information gained from this study will help to better understand the brain processes associated with depression and its successful treatment.
Condition | Intervention |
---|---|
Depression |
Drug: Escitalopram |
Study Type: | Interventional |
Study Design: | Treatment, Open Label, Single Group Assignment, Efficacy Study |
Official Title: | ERPs, Cognitive Dysfunction and Treatment Response of Geriatric Depression |
Estimated Enrollment: | 120 |
Study Start Date: | May 2007 |
Estimated Study Completion Date: | May 2012 |
Estimated Primary Completion Date: | May 2012 (Final data collection date for primary outcome measure) |
Ages Eligible for Study: | 60 Years to 85 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Active treatment with fluoxetine at the time of screening
United States, New York | |
Weill Cornell Medical College-Westchester Division | Recruiting |
White Plains, New York, United States, 10605 | |
Contact: Christy Lim 914-997-4331 | |
Principal Investigator: George Alexopoulos, MD |
Principal Investigator: | George Alexopoulos, MD | Weill Cornell Medical College |
Responsible Party: | Weill Cornell Medical College ( George Alexopoulos, MD ) |
Study ID Numbers: | R01 MH079414-01A1, R01 MH079414-01A1 |
Study First Received: | September 17, 2008 |
Last Updated: | March 10, 2009 |
ClinicalTrials.gov Identifier: | NCT00754936 History of Changes |
Health Authority: | United States: Institutional Review Board |
Neurotransmitter Agents Depression Psychotropic Drugs Depressive Disorder Citalopram Serotonin Uptake Inhibitors Serotonin |
Behavioral Symptoms Mental Disorders Mood Disorders Dexetimide Antidepressive Agents, Second-Generation Antidepressive Agents |
Neurotransmitter Agents Neurotransmitter Uptake Inhibitors Depression Molecular Mechanisms of Pharmacological Action Physiological Effects of Drugs Psychotropic Drugs Depressive Disorder Citalopram Serotonin Uptake Inhibitors |
Pharmacologic Actions Behavioral Symptoms Serotonin Agents Mental Disorders Therapeutic Uses Mood Disorders Antidepressive Agents, Second-Generation Central Nervous System Agents Antidepressive Agents |